Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells take aim at Hard-to-Treat lymphoma

NCT ID NCT04083495

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times

Summary

This study tests a new treatment for people with a rare blood cancer called peripheral T-cell lymphoma that has not responded to standard therapy or has returned. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells carrying a specific marker (CD30). About 20 adults will receive the modified cells after a short course of chemotherapy to prepare the body. The goal is to see if this approach can control the cancer and how long that control might last.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lineberger Comprehensive Cancer Center at University of North Carolina

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Wake Forest Baptist Medical Center

    RECRUITING

    Winston-Salem, North Carolina, 27157, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.